Search clinical trials for: dihydroergotamine mesylate

Total 1651 results

Second Affiliated Hospital of Soochow University

Active, not recruiting

A Clinical Study of Dihydroergotine Mesylate Extended-release Tablets for the Treatment of Drooling in Parkinson's Disease.

Salivation in Parkinson's Disease

China
Satsuma Pharmaceuticals, Inc.

Completed

A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Migraine | Migraine Without Aura | Migraine With Aura

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine (EMERGE)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Thomas Jefferson University
Bausch Health Americas, Inc.

Completed

A Study Examining the Use of a Migraine Medicine in the Treatment of Two Migraine Attacks in Patients Who Have Increased Skin Sensitivity

Migraine

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects

Migraine | Migraine Without Aura | Migraine With Aura

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine (SUMMIT)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Satsuma Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine (ASCEND)

Migraine | Migraine Without Aura | Migraine With Aura

United States
Impel Pharmaceuticals

Completed

Bioavailability of DHE Administered by I123 POD Device, IV Injection, and Migranal Nasal Spray in Healthy Adults

Migraine Headache

Australia
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Impel Pharmaceuticals

Completed

Safety and Tolerability of POD-DHE (INP104) in Migraine (STOP 301)

Migraine Headache

United States
Allergan
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan

Completed

Pharmacodynamic Study to Compare Acute Effects of Dihydroergotamine Mesylate (DHE) on Pulmonary Arterial Pressure

Healthy

United States
Sinphar Pharmaceutical Co., Ltd

Completed

Study of STA-1 Capsule in Patients With Vascular Dementia (Marrow-Sea Deficiency)

Vascular Dementia

China
University of Bologna

Completed

Exploratory Study of IMATINIB High Dose in Intermediate Risk Chronic Myeloid Leukemia in Chronic Phase

Myeloid Leukemia, Chronic, Chronic-Phase

Italy
Chengdu Zenitar Biomedical Technology Co., Ltd

Completed

Study of Prilinostat Mesylate for Injection in the Treatment of Relapsed or Refractory B Cell-related Tumor-predominant

Diffuse Large B Cell Lymphoma，DLBCL

China
Novartis Pharmaceuticals

Completed

Imatinib Mesylate in Patients With Refractory Desmoplastic Small Round Cell Tumors

Refractory Desmoplastic Small Round Cell Tumors

Italy
IlDong Pharmaceutical Co Ltd

Completed

A Phase I Study of IDP-73152 Mesylate in Health Male Volunteer (PDF inhibitor)

Healthy

Korea, Republic of
Elizabeth Berry-Kravis

Completed

Single Blind Study of Ergoloid Mesylates, 5-HTP and the Combination in Adult Males With Fragile X Syndrome

Fragile X Syndrome

United States
Ache Laboratorios Farmaceuticos S.A.

Withdrawn

Cefaliv® Compared to Neosaldina® in the Treatment of Migraine Attacks

Migraine Headache

Brazil
Thomas Jefferson University

Completed

A Research Study Examining Migranal and Skin Sensitivity in Subjects With Migraine

Migraine

United States
Calgent Biotechnology Co., Ltd

Completed

Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors

Resistant or Refractory Solid Tumors

United States, Taiwan
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Inc.

Approved for marketing

An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory

Metastatic Breast Cancer

Canada, Belgium, France
Merz Pharmaceuticals GmbH

Terminated

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus (OLLTT)

Subjective Tinnitus

United States, United Kingdom, Poland, Austria, Belgium, Brazil, Czech Republic, France, Germany, Mexico, Netherlands, Portugal, South Africa, Spain
Pathway Therapeutics, Inc.

Completed

Study of PWT33597 Mesylate in Subjects With Advanced Malignancies

Malignancies

United States
Merz Pharmaceuticals GmbH

Terminated

Open-lable Extension Study on Safety and Efficacy of Neramexane to Treat Congenital and Acquired Nystagmus

Multiple Sclerosis | Nystagmus, Congenital | Nystagmus, Acquired

United Kingdom
Merz Pharmaceuticals GmbH

Completed

Investigate the Effect of Neramexane Mesylate IR Tablet on Driving Fitness and Capability to Operate Machines in Healthy Volunteers

Healthy

Germany
Eisai Inc.

Completed

Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies

Breast Cancer

United States
Eisai Co., Ltd.

Completed

Study of E7389 for Advanced or Metastatic Breast Cancer

Breast Cancer

Japan
Nanjing First Hospital, Nanjing Medical University

Enrolling by invitation

Mid-and Long-term Efficacy of Ergot Alkaloids in the Treatment of Salivation in Patients With Parkinson's Disease.

Main Heading (Descriptor) Terms

China
Eisai Limited

Completed

QT Interval Prolongation Study of Eribulin Mesylate (E7389) in Patients With Advanced Solid Tumors

Advanced Solid Tumor

France
Centre Leon Berard

Completed

Efficiency of Imatinib Treatment Maintenance or Interruption After 3 Years of Adjuvant Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (ImadGist)

Gastrointestinal Stromal Tumors | Resected Gastrointestinal Stromal Tumors | Non-metastatic | High Risk of Recurrence | KIT Gene Mutation

France
Hunan Cancer Hospital

Completed

Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast Cancer

Metastatic Breast Cancer

China
Oncologia Medica dell'Ospedale Fatebenefratelli
Mario Negri Institute for Pharmacological Research

Completed

PAINTER: Polymorphism And INcidence of Toxicity in ERibulin Treatment

Metastatic Breast Cancer | Toxicity | Neurotoxicity | Adverse Drug Event | Drug Toxicity

Italy
The First Affiliated Hospital with Nanjing Medical...

Not yet recruiting

Maintenance Treatment With Eribulin Mesylate Versus Observation in Triple Negative Breast Cancer Patients (EMBRAVE-001)

Triple Negative Breast Cancer

China
National Cancer Institute (NCI)

Completed

S0618 E7389 in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

Head and Neck Cancer

United States
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety, Tolerability of Neramexane in Patients With Subjective Tinnitus

Subjective Tinnitus

United States, Austria, Germany, Brazil, Mexico
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Comparison to Placebo in Patients With Subjective Tinnitus

Subjective Tinnitus

Belgium, Czech Republic, France, Poland, South Africa, Netherlands
Cancer Institute and Hospital, Chinese Academy...

Recruiting

Eribulin Mesylate Combined With Lobaplatin in the Treatment of Recurrent or Metastatic Triple-negative Breast Cancer

Triple Negative Breast Cancer

China
Eisai Inc.

Completed

A Study to Evaluate Safety, Tolerability and Efficacy of Eribulin Mesylate in Treating Adult Females With Locally Advanced or Metastatic Breast Cancer

Breast Neoplasms

India
Eisai Inc.
Children's Oncology Group

Completed

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas (BOLD 113)

Solid Tumors | Pediatrics

United States
Chang Gung Memorial Hospital
Eisai Co., Ltd.; Kaohsiung Breast Cancer Prevention and Education Society (KBCPES)

Unknown

Halaven Patient Registry (Metastatic Breast Cancer, MBC)

Advanced Breast Cancer | Metastatic Breast Cancer

Taiwan
Eisai Co., Ltd.

Completed

An Open-label, Multicenter, Phase 2 Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Previously Treated Subjects With Advanced or Metastatic Soft Tissue Sarcoma (Study E7389-J081-217)

Soft Tissue Sarcoma

Japan
Merz Pharmaceuticals GmbH

Completed

Efficacy, Safety and Tolerability of Neramexane in Patients With Subjective Tinnitus (EASE)

Subjective Tinnitus

Germany, Portugal, Spain, United Kingdom, Austria
Eisai Inc.

Completed

Study Of Eribulin (E7389) In Patients With Advanced Solid Tumors And Normal Or Reduced Hepatic Function As Per Child-Pugh System

Cancer

Netherlands
Seoul National University Hospital

Recruiting

Eribulin With or Without Trastuzumab-biosimilar in Patients With HER2-overexpressed Recurrent or Stage IV Breast Cancer (ESPERO)

Advanced Breast Cancer

Korea, Republic of
InteKrin Therapeutics, Inc.

Completed

A Safety and Efficacy Study of T0903131 (INT131) Besylate to Treat Type 2 Diabetes Mellitus

Diabetes Mellitus, Type II

United States
Kimberly S Jones

Terminated

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

Migraine in Children

United States
Cancer Research UK
Latus Therapeutics

Terminated

A Trial Looking at the Use of Camostat in People Who Have Tested Positive for Coronavirus (COVID-19) (SPIKE-1) (SPIKE-1)

COVID-19 Infection

United Kingdom
Celgene

Completed

Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment

Hepatic Impairment

United States
Celgene

Completed

A Study to Assess the Pharmacokinetics of Enasidenib (CC-90007) in Subjects With Moderate and Severe Hepatic Impairment.

Hepatic Impairment

United States

3

Subscribe